Impact of New Immunological Diagnosis Tests of Latent Tuberculosis Before Anti TNF Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

430 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-12-31

Study Completion Date

2012-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Tuberculosis is a current infection during anti TNF therapy. After infectious contact, some patients will develop tuberculosis and some will only be infected without symptoms, they have Latent Tuberculosis Infection (LTBI) wich can reactivate later. In order to prevent this tuberculosis reactivation, LTBI diagnosis screening is preconised in patients who need anti TNF therapy. This diagnosis is made till now by the tuberculin skin test (TST) but this test is not specific of TB. New blood tests (QFTB-G and T-SPOT.TB) specific to MTB infection are now available.

The primary endpoint of this study is the evaluation of the theoric therapeutic impact of the use of new tests for diagnosis of LTBI in patients before anti TBF therapy

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Medical and Economical Impact of IGRAs Diagnosis of Latent Tuberculosis in HIV-infected Patients

NCT00805272

HIV Tuberculosis Latent Tuberculosis Infection

COMPLETED NA

Serological Test for the Diagnosis of TB

NCT02898623

Active Tuberculosis

TERMINATED

Evaluation of a Novel Microbiological Diagnostic Test for Latent Mycobacterium Tuberculosis Infection

NCT06728930

Latent Tuberculosis Infection Tuberculosis Infection, Latent

ENROLLING_BY_INVITATION

Demonstration of the Dynamic Hypothesis of Latent Tuberculosis Infection

NCT00905970

Latent Tuberculosis Infection

UNKNOWN

New Strategies for Assessment of the Persistence of Viable Bacilli in Latent and Active Tuberculosis

NCT05621343

Latent Tuberculosis Persistent Infection Mycobacterium Tuberculosis

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Detailed description :

Principal outcome: Therapeutic impact of the use of new tests for diagnosis of LTBI in patients before anti TBF therapy

Secondary outcomes :

* medico-economic impact of replacement of TST by QFTB-G and T-SPOT.TB tests in LTBI screening in patients before anti TNF therapy.
* concordance of QFTB-G and T-SPOT.TB tests results with TST
* Concordance between QFTB-G and T-SPOT.TB tests and evaluation of indetermined tests.
* concordance of QFTB-G and T-SPOT.TB tests results with patient disease.
* concordance of QFTB-G and T-SPOT.TB tests results with TST in patients with LTBI determinated by clinical or radiological observation
* Impact of geographical, disease and treatment in patients with LTBI determinated by clinical or radiological observation
* Identify the original characteristic and maximal impact therapeutic of QFTB-G and T-SPOT.TB test

Analysed criteria :

* therapeutic impact
* Patients percentage with different therapeutic outcome based on usual recommendations medico-economic
* Medico-economic impact :impact of both tests as early and late cost - efficacy

Statistic :

* Primary criteria : Percentage of patients for whom therapeutic would have been changed by QFTB-G and T-SPOT.TB tests results compared to usual diagnosis strategy.
* Secondary criteria : Concordance of QFTB-G and T-SPOT.TB tests with TST Concordance between both QFTB-G and T-SPOT.TB tests .

400 patients Timing : inclusions : 1 years

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tuberculosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

QFTB-G and T-SPOT.TB tests

Intervention Type BIOLOGICAL

QFTB-G and T-SPOT.TB test before TST

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

QFTB-G and T-SPOT.TB tests

QFTB-G and T-SPOT.TB test before TST

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

There are no arms currently listed for this study.

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years old
* Patient with rheumatoid arthritis or Ankylosing spondylitis or Crohn's disease
* Patient without Anti TNF treatment and who need one by infliximab, adalimumab or etanercept
* Consent signed
* Patient with social right
* Patient who have been examined